Perrigo Company plc (NYSE:PRGO) has agreed to sell UK-based unit Rosemont Pharmaceuticals, a maker of generic medicines focused on liquid formulations, to an unnamed private equity shop for £156M (~$195M) in cash.
The company says the deal was signed and closed on the same day.
Rosemont contributed $53M in sales and $0.12 in non-GAAP EPS to Perrigo’s 2019 results.
https://seekingalpha.com/news/3584501-perrigo-jettisons-uk-unit-for-156m-to-pe-firm
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.